Avalere Health Deepens Expertise in Market Access and Policy Analytics
Summary
Two new hires come to the firm with significant experience in US healthcare.
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.
John Neal, Managing Director, and Rebecca Yip, Principal, have joined Avalere Health.
About John Neal
In John’s new role with the Market Access practice, he will be partnering with pharmaceutical and biotechnology clients to develop access strategies to inform pre-launch planning and decision making designed to ensure successful commercialization of products. John comes to Avalere with more than 20 years of experience in the life sciences sector and has delivered results in launch planning, pricing, and market access strategy development with specialized therapeutic knowledge in multiple sclerosis, immuno-oncology, and vaccines. John previously held commercial leadership positions at EMD Serono, GlaxoSmithKline, and Novartis.
“Life sciences and biotech companies need thoughtful market strategies to ensure that their products get to the right patients at the right time,” said Lance Grady, Practice Director at Avalere. “John Neal’s proven experience in preparing to launch complex and emerging therapeutic areas is a tremendous asset to Avalere and to our clients that are looking for a strategic partner to help shape comprehensive solutions.”
About Rebecca Yip
In Rebecca’s new role with Avalere’s Policy practice, she will be collaborating with clients to help them better understand the quantitative implications of healthcare policy on their businesses. Rebecca comes to the firm with more than 20 years’ experience in both the public and private sectors, providing analyses of health policy and market research involving federal programs, the commercial sector, and prescription drugs. Prior to joining Avalere, Rebecca was a principal analyst at the Congressional Budget Office where she led analyses for Medicare Part D and pharmacy policies. Rebecca has also held positions at Squire Patton Boggs LLP, Pfizer Health Solutions Inc, and PricewaterhouseCoopers LLP.
“It is more important than ever for healthcare stakeholders to quantify the impact of public policy change,” said Kelly Brantley, Practice Director at Avalere. “Rebecca Yip’s experience modeling complex policy will be an asset to any company looking to stay a step ahead, particularly in Medicare Part D.”
To receive Avalere updates, connect with us.
Related Content
Services
From beginning to end, our team synergy
produces measurable results. Let's work together.
produces measurable results. Let's work together.
